• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

bladder cancer

Graphic of a number of arrows missing the bullseye on a target except for one arrow
Biotech

CG’s newest late-stage bladder cancer results broaden potential

CG Oncology’s phase 3 results show that its immunotherapy can have a wider impact on certain patients with non-muscle invasive bladder cancer.
Michael Gibney Nov 16, 2026 2:05pm
Doctor examining red diagram of urinary system

Virtuoso abs FDA OK for robotic bladder lesions system

Nov 13, 2026 3:54am
positive negative up down good bad mixed

Tyra rolls toward pivotal cancer study even as stock deflates

Sep 9, 2026 9:30am
Eli Lilly booth at AACR 2026

ASCO: Lilly debuts ‘strong’ data for potential Padcev challenger

May 29, 2026 8:00am
downfall

EnGene cancer sales forecast cut after new data widen gap to J&J

May 8, 2026 9:08am
cancer target detection radiopharma radio

Protara sees 66% bladder cancer response rate at 6 months

Feb 24, 2026 6:50am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings